Welcome to our dedicated page for Visionary Holdings news (Ticker: GV), a resource for investors and traders seeking the latest updates and insights on Visionary Holdings stock.
Visionary Holdings Inc. reports developments tied to its healthcare, biotechnology, and medical-aesthetics focus, including commercialization activity for anti-aging and regenerative wellness products. Company updates have covered V-series anti-aging products, RAMU-related products, Premier Regenerative Complex-President Super Injection, distribution arrangements, channel development, and healthcare service collaborations in markets including China.
Recurring news also includes Nasdaq listing-compliance matters for GV common shares, periodic reporting status, listing-fee notices, shareholder voting matters, governance actions, capital-structure disclosures, and operating and financial results.
Visionary Holdings (NASDAQ: GV) entered a December 2025 private placement, issuing a $500,000 senior secured convertible promissory note for $450,000 gross proceeds. The note matures on December 11, 2026, accrues interest at the greater of prime+4.5% or 9% (semi‑annual payments) and jumps to 18% on default.
The note is convertible at the investor’s option into common stock at $1.44 per share, subject to Nasdaq rules and customary adjustments; terms update and differ from the prior January 31, 2025 note (principal $1,500,000; conversion price $2.25).
Visionary Holdings (Nasdaq: GV) announced Nasdaq has closed a listing deficiency after the company filed its Annual Report on Form 20-F for the year ended March 31, 2025.
Visionary filed the Form 20-F on January 28, 2026; Nasdaq issued a compliance confirmation on January 29, 2026, confirming continued listing and closure of the matter.
Visionary Holdings (Nasdaq: GV) regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Annual Report on Form 20-F for the fiscal year ended March 31, 2025.
The company filed the Form 20-F on January 28, 2026, and Nasdaq advised on January 29, 2026 that the matter is closed. Visionary reiterated its commitment to maintaining full compliance with Nasdaq listing standards and U.S. securities laws.
Visionary Holdings (Nasdaq: GV) released its final annual report and audited financial statements for the fiscal year ended March 31, 2025; the Form 20-F filing with the SEC is pending. FY2025 revenue was $5.04M, down 46.2% YoY, with real estate leasing $2.80M, education $1.18M and emerging health businesses $1.06M (≈21.1% of revenue). The company recorded a net loss of $15.75M, including ~$4.70M in asset impairment charges. Total assets were $63.63M and negative working capital was about $54.50M. Management is pursuing equity financing, creditor negotiations, and strategic growth in health management, anti-aging, and premium medical aesthetics while strengthening governance.
Visionary Holdings (Nasdaq: GV) released its finalized annual report and audited financial statements for the fiscal year ended March 31, 2025; Form 20-F filing with the SEC is pending.
Key metrics: FY2025 revenue $5.04M (-46.2% YoY), net loss $15.75M, emerging health businesses revenue $1.06M (~21.1% of total), asset impairment ~$4.70M, and negative working capital ~$54.50M. Management cites transformation investments, financing pressures, creditor negotiations, and plans to pursue health management, anti-aging, premium medical aesthetics, and AI education initiatives.
Visionary Holdings (Nasdaq: GV) filed its Annual Report for fiscal 2025 (year ended Mar 31, 2025) outlining a strategic shift from education and real estate toward health management, anti-aging, and premium medical aesthetics alongside an AI-enabled education business. Total revenue was USD 5.04 million (-46.2% YoY); emerging health businesses contributed ~21.1% of revenue. The company reported a net loss of USD 15.75 million, including ~USD 4.70 million of asset impairment charges, and cited ~USD 54.50 million negative working capital and ongoing liquidity pressures. Management plans further commercialization, strategic collaborations, governance enhancements, and potential financings.
Visionary Holdings (GV) announced governance changes, a strategic pivot to anti-aging high-end medical aesthetics, two September 2025 partnerships, and a timeline for its annual report filing.
Key facts: a new nine-member Board was elected on October 29, 2025; Xiyong Hou named CEO with Jun Huang as Co-CEO; Assentsure PAC reappointed auditor for 2025-2026; partnerships with Jiangsu Yike Regenerative Medicine (global R&D cooperation) and a joint venture with Anhui Weikang Kangling to build an anti-aging health center in Toronto; draft Form 20-F for year ended March 31, 2025 is under final review and expected filed on or before January 12, 2026.
Visionary Holdings (Nasdaq: GV) appointed Wenxuan Cai as CEO of its health technology subsidiary GV Hong Kong, effective Dec 30, 2025, and established a wholly owned Nanjing sales entity focused on regional sales and market development.
The company says this completes a fully integrated commercial structure across strategy, products and sales execution, marking a shift from strategic positioning to active, on-the-ground revenue generation in cellular rejuvenation and aesthetic treatment markets across Asia.
Visionary Holdings (Nasdaq: GV) announced on Nov 10, 2025 the commercial launch of a medical-grade stem cell anti-aging product line via its Hong Kong subsidiary, targeting the Chinese mainland, Hong Kong and Singapore with later expansion planned to Southeast Asia and North America.
GV said it has integrated a global technology licensing agreement with Jiangsu Yike Regenerative Medicine into three core product packages: the flagship Life Rejuvenation Program (mesenchymal stem cells, NK cell therapy, AI diagnostics), a Precision Repair Package with DFPP blood purification, and a Premium Personalized Program including full-genome sequencing and annual customized management.
Planned commercialization steps include a joint-venture production/clinical base, cross-border sales and branded clinic partnerships to support localized manufacturing and market rollout.
Visionary Holdings (NASDAQ: GV) held its First Meeting of the Fourth Board of Directors on November 3, 2025 and unanimously adopted governance resolutions to standardize oversight and operations.
The board elected William T. Chai as Chairman and installed a senior management team: Xiyong Hou (CEO), Jun Huang (Co-CEO), Robert Jay Lees (COO) and Xiaolan Liu (CFO). The company also formed four specialized committees (Audit, Nomination, Compensation, Investment) and adopted committee rules, job descriptions, and company secretary work rules to clarify responsibilities and strengthen compliance.
Resolutions were disclosed via the company website and NASDAQ within 48 hours, emphasizing a focus on high-end stem cell aesthetics and big health technology strategy.